DD this is how I see it what happened
1. We know that the conference presentation was never meant to be held prior to TLD + Publication so during the quiet time.
=> Bosch must have been receiving many emails from the conference months prior and right up till the conference. So the conference and his responsibility for his attendance must have been on his mind all that time. Therefore if he knew weeks before the start of the conference that TLD + Publication would take a long time he would have canceled weeks before.
2. On Monday, January 10 MB was made aware by either email or a phone call from the event manager that his time of appearance had been shifted for Jan 20 from 11..40 to 12.10.
One thing Im convinced about the conference was supposed to be after results had been disclosed. There is just no way NWBO will present anything in their quiet period. I think it was kinda not on MB's radar when he got the email Thursday, got reminded, and canceled.
MB is definitely a co-author as he was in May 2018.
That to me indicates and I'm speculation now I realize that, that they still have not a definite publication date. Could be peer-reviewing which I suspect could be the last details.. we don't know where they are .
at what point will NWBO get a name for constantly pulling out of conferences? Seriously. This must be a huge nuisance to the glioblastoma-drugdevelopment conference organization they pulled out 4 days before it started, people are paying admittance.
NWBO needs continuous FDA permission to sell DCVAX L as compassionate treatment, which we know for a few days now is exactly what they are doing, has just started up, in Sawston. FDA has seen the data for sure, combine the two and you know what time it is.
that is correct
Moreover, the FDA and the MHRA have permitted the continuation of the compassionate sales of DCVAX L in Sawston after the FDA has become aware of the unblinded data. It would be beyond bizarre if in the near future the FDA would turn around and disapprove DCVAXL after the BLA is submitted.
Your explanation makes sense. If the presentation was always intended prior to TLD / journal as we have seen Dr Liau's last year then they would have not canceled. Something very short notice came up so they had to cancel and if I had to guess it is NEJM letting NWBO know they had to move the publication to another time frame.
You have to give Bosch a bit more credit then that he would not have confounded the trial results, he is NWBOs CTO and co author!
Let’s say they planned max 2 weeks between TLD and the journal and Bosch just after TLD. It would not surprise me if NEJM called them yesterday and told them they have to move the publication to half feb. In that case it would leave them no choice to cancel Bosch. If the publication were not ready yet then they would have known that weeks ago and cancelled a lot sooner. IMO
Title and time now stripped from his speaking slot.
another placeholder removed?
One thing we can be sure of is the FDA has seen trial data and if they did not like the data they would have stopped/warned NWBO from proceeding with the compassionate treatment as what they are doing now, full steam ahead.
What signal would the FDA, UK/EMA give if they later this year would dismiss DCVAX L to patients that have been treated.
many have asked you questions that you have left unanswered so Im a bit reluctant to answer your question for that reason. But ok.
There are certain circles that have proven to be very reliable to me even more so than LG. And that is because LG has not been that reliable over the years. So firsthand info does not need to be super reliable perse.
But my sources are the second of your equation and your conclusion that such is thus less trustworthy is not my experience.
I think the delay of results is due to the delay of the publication which is in turn due to covid. I have heard (reliable outside this board) its very very close (publication).
Since the publication is not in the hands of NWBO it would be a complete waste of time if meanwhile, NWBO had not worked on BLA and expedited approval but in what phase that is I have no idea.